Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

The necessity for rigour in rare disease study design.

Baker LH.

Lancet Oncol. 2019 Sep;20(9):1190-1192. doi: 10.1016/S1470-2045(19)30323-7. Epub 2019 Jul 19. No abstract available.

PMID:
31331700
2.

Patient Perceptions of Survivorship Care Plans: A Mixed-Methods Evaluation.

Antalis EP, Doucette R, Kuhn G, Baker LH, Reinke D.

Oncol Nurs Forum. 2019 Jul 1;46(4):493-502. doi: 10.1188/19.ONF.493-502.

PMID:
31225833
3.

In Memoriam: Charles A. Coltman, 1930 to 2018.

Blanke CD, Crowley J, Baker LH, Fisher RI.

J Clin Oncol. 2019 May 1;37(13):1037-1040. doi: 10.1200/JCO.19.00270. Epub 2019 Mar 12. No abstract available.

PMID:
31026409
4.

Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases.

Siontis BL, Zhao L, Leja M, McHugh JB, Shango MM, Baker LH, Schuetze SM, Chugh R.

Sarcoma. 2019 Mar 10;2019:1960593. doi: 10.1155/2019/1960593. eCollection 2019.

5.

Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices.

Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL.

JAMA Oncol. 2019 Apr 1;5(4):497-505. doi: 10.1001/jamaoncol.2018.6437. Erratum in: JAMA Oncol. 2019 Mar 7;:.

PMID:
30653226
6.

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.

Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH.

JAMA Oncol. 2018 Jun 1;4(6):814-820. doi: 10.1001/jamaoncol.2018.0601.

7.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S.

Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Erratum in: Lancet Oncol. 2018 Jan;19(1):e8.

PMID:
28988646
8.

Integrative clinical genomics of metastatic cancer.

Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieślik M, Chinnaiyan AM.

Nature. 2017 Aug 17;548(7667):297-303. doi: 10.1038/nature23306. Epub 2017 Aug 2.

9.

Reduced infectivity of waterborne viable but nonculturable Helicobacter pylori strain SS1 in mice.

Boehnke KF, Eaton KA, Fontaine C, Brewster R, Wu J, Eisenberg JNS, Valdivieso M, Baker LH, Xi C.

Helicobacter. 2017 Aug;22(4). doi: 10.1111/hel.12391. Epub 2017 Apr 24.

10.

Next generation sequencing of extraskeletal myxoid chondrosarcoma.

Davis EJ, Wu YM, Robinson D, Schuetze SM, Baker LH, Athanikar J, Cao X, Kunju LP, Chinnaiyan AM, Chugh R.

Oncotarget. 2017 Mar 28;8(13):21770-21777. doi: 10.18632/oncotarget.15568.

11.

Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru.

Boehnke KF, Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, Novoa Reyes I, Crowley JJ, Baker LH, Xi C.

Infect Drug Resist. 2017 Mar 10;10:85-90. doi: 10.2147/IDR.S123798. eCollection 2017.

12.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728. Erratum in: JAMA Oncol. 2017 Jul 1;3(7):1002.

13.

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.

Schuetze SM, Bolejack V, Choy E, Ganjoo KN, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M, D'Amato G, Leu KM, Loeb DM, Forscher CA, Milhem MM, Rushing DA, Lucas DR, Chugh R, Reinke DK, Baker LH.

Cancer. 2017 Jan 1;123(1):90-97. doi: 10.1002/cncr.30379. Epub 2016 Oct 3.

14.

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.

Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH.

J Clin Oncol. 2016 Oct 20;34(30):3680-3685. doi: 10.1200/JCO.2016.68.1858.

15.

SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy.

Davis EJ, Zhao L, Lucas DR, Schuetze SM, Baker LH, Zalupski MM, Thomas D, Chugh R.

BMC Cancer. 2016 Aug 20;16:663. doi: 10.1186/s12885-016-2694-2.

16.

The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health.

Bobowski NP, Baker LH.

J Adolesc Young Adult Oncol. 2016 Sep;5(3):211-4. doi: 10.1089/jayao.2016.0004. Epub 2016 Apr 26.

17.

Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group.

Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carlson JJ.

Med Decis Making. 2016 Jul;36(5):641-51. doi: 10.1177/0272989X16636847. Epub 2016 Mar 24.

18.

Contemporary Concerns in Managing Bone Sarcoma.

Baker LH.

J Oncol Pract. 2016 Mar;12(3):217-8. doi: 10.1200/JOP.2015.010181. No abstract available.

PMID:
26962161
19.

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.

Bid HK, Phelps DA, Xaio L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ.

Mol Cancer Ther. 2016 May;15(5):1018-28. doi: 10.1158/1535-7163.MCT-15-0567. Epub 2016 Feb 23.

20.

Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.

Hyun O J, Luber BS, Leal JP, Wang H, Bolejack V, Schuetze SM, Schwartz LH, Helman LJ, Reinke D, Baker LH, Wahl RL.

J Nucl Med. 2016 May;57(5):735-40. doi: 10.2967/jnumed.115.162412. Epub 2016 Jan 21.

21.

SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.

Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, Reinke DK, Baker LH.

Cancer. 2016 Mar 15;122(6):868-74. doi: 10.1002/cncr.29858. Epub 2015 Dec 28.

22.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

23.

Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.

Cobain EF, Chinnaiyan AM, Kurzrock R, Baker LH.

JAMA Oncol. 2015 Jul;1(4):542. doi: 10.1001/jamaoncol.2015.0942. No abstract available.

PMID:
26181268
24.

A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.

Davis EJ, Chugh R, Zhao L, Lucas DR, Biermann JS, Zalupski MM, Feng M, Wong SL, Jacobson J, Zyczynski L, Reinke D, Metko G, Baker LH, Schuetze SM.

Eur J Cancer. 2015 Sep;51(13):1794-802. doi: 10.1016/j.ejca.2015.05.010. Epub 2015 Jun 9.

PMID:
26066736
25.

Animal Model Reveals Potential Waterborne Transmission of Helicobacter pylori Infection.

Boehnke KF, Eaton KA, Valdivieso M, Baker LH, Xi C.

Helicobacter. 2015 Oct;20(5):326-33. doi: 10.1111/hel.12216. Epub 2015 Feb 9.

26.

Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.

Andersen NJ, Nickoloff BJ, Dykema KJ, Boguslawski EA, Krivochenitser RI, Froman RE, Dawes MJ, Baker LH, Thomas DG, Kamstock DA, Kitchell BE, Furge KA, Duesbery NS.

Mol Cancer Ther. 2013 Sep;12(9):1701-14. doi: 10.1158/1535-7163.MCT-12-0893. Epub 2013 Jun 26.

27.

Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.

Redman MW, Goldman BH, LeBlanc M, Schott A, Baker LH.

Clin Cancer Res. 2013 May 15;19(10):2646-56. doi: 10.1158/1078-0432.CCR-12-2939.

28.

Generic sirolimus: a future opportunity to decrease the cost of oncology care?

Baker LH.

Clin Adv Hematol Oncol. 2013 Feb;11(2):102-3. No abstract available.

PMID:
23598911
29.

Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process.

Deverka PA, Lavallee DC, Desai PJ, Armstrong J, Gorman M, Hole-Curry L, O'Leary J, Ruffner BW, Watkins J, Veenstra DL, Baker LH, Unger JM, Ramsey SD.

J Comp Eff Res. 2012 Jul;1(4):359-70.

30.

Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.

Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Peña EM, Peña R, Correa P, Martínez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE, Crowley JJ, Baker LH.

JAMA. 2013 Feb 13;309(6):578-86. doi: 10.1001/jama.2013.311.

31.

Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LH.

Cancer. 2013 Apr 15;119(8):1555-61. doi: 10.1002/cncr.27942. Epub 2013 Jan 18.

32.

Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701).

Porras C, Nodora J, Sexton R, Ferreccio C, Jimenez S, Dominguez RL, Cook P, Anderson G, Morgan DR, Baker LH, Greenberg ER, Herrero R.

Cancer Causes Control. 2013 Feb;24(2):209-15. doi: 10.1007/s10552-012-0117-5. Epub 2012 Dec 12.

33.

Moving a randomized clinical trial into an observational cohort.

Goodman PJ, Hartline JA, Tangen CM, Crowley JJ, Minasian LM, Klein EA, Cook ED, Darke AK, Arnold KB, Anderson K, Yee M, Meyskens FL, Baker LH.

Clin Trials. 2013 Feb;10(1):131-42. doi: 10.1177/1740774512460345. Epub 2012 Oct 12.

34.

When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, Schwartz LH.

J Natl Cancer Inst. 2012 Oct 17;104(20):1534-41. doi: 10.1093/jnci/djs353. Epub 2012 Aug 27.

35.

Randomization and statistical power: paramount in trial reproducibility (even for rare cancers).

Baker LH, Crowley JJ, Maki RG.

Oncologist. 2012;17(9):1129-32. Epub 2012 Aug 22. No abstract available.

36.

Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.

Schuetze SM, Zhao L, Chugh R, Thomas DG, Lucas DR, Metko G, Zalupski MM, Baker LH.

Eur J Cancer. 2012 Jun;48(9):1347-53. doi: 10.1016/j.ejca.2012.03.022. Epub 2012 Apr 21.

PMID:
22525224
37.

Cancer survivors in the United States: a review of the literature and a call to action.

Valdivieso M, Kujawa AM, Jones T, Baker LH.

Int J Med Sci. 2012;9(2):163-73. doi: 10.7150/ijms.3827. Epub 2012 Jan 17. Review.

38.

Prioritization in comparative effectiveness research: the CANCERGEN Experience.

Thariani R, Wong W, Carlson JJ, Garrison L, Ramsey S, Deverka PA, Esmail L, Rangarao S, Hoban CJ, Baker LH, Veenstra DL; Center for Comparative Effectiveness Research in Cancer Genomics (CANCERGEN).

Med Care. 2012 May;50(5):388-93. doi: 10.1097/MLR.0b013e3182422a3b.

39.

Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.

Ha HT, Griffith KA, Zalupski MM, Schuetze SM, Thomas DG, Lucas DR, Baker LH, Chugh R.

Am J Clin Oncol. 2013 Feb;36(1):77-82. doi: 10.1097/COC.0b013e31823a4970.

PMID:
22237145
40.

How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment.

Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, Baker LH.

Health Aff (Millwood). 2011 Dec;30(12):2259-68. doi: 10.1377/hlthaff.2010.0637.

41.

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD.

J Clin Oncol. 2012 Jan 1;30(1):78-84. doi: 10.1200/JCO.2011.35.6329. Epub 2011 Nov 7. Erratum in: J Clin Oncol. 2017 Aug 10;35(23):2722.

PMID:
22067397
42.

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.

Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH.

J Clin Oncol. 2011 Dec 1;29(34):4541-7. doi: 10.1200/JCO.2010.34.0000. Epub 2011 Oct 24.

43.

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH.

JAMA. 2011 Oct 12;306(14):1549-56. doi: 10.1001/jama.2011.1437.

44.

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.

Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH.

Lancet. 2011 Aug 6;378(9790):507-14. doi: 10.1016/S0140-6736(11)60825-8. Epub 2011 Jul 21.

45.

SWOG Cooperative Group biorepository resource: access for scientific research studies.

Hoban CJ, Franklin W, Kopecky KJ, Baker LH.

Clin Cancer Res. 2011 Aug 15;17(16):5239-46. doi: 10.1158/1078-0432.CCR-10-3138. Epub 2011 May 9.

46.

Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.

Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, Benjamin RS, Baker LH; Sarcoma Alliance for Research through Collaboration (SARC).

Clin Cancer Res. 2010 Oct 1;16(19):4884-91. doi: 10.1158/1078-0432.CCR-10-1177. Epub 2010 Aug 19.

47.

Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.

Saraiya B, Chugh R, Karantza V, Mehnert J, Moss RA, Savkina N, Stein MN, Baker LH, Chenevert T, Poplin EA.

Invest New Drugs. 2012 Feb;30(1):258-65. doi: 10.1007/s10637-010-9504-5. Epub 2010 Aug 10.

48.

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.

Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Reaman GH, Baker LH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S.

Leukemia. 2010 May;24(5):909-13. doi: 10.1038/leu.2010.56. Epub 2010 Apr 8.

49.

Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.

Verweij J, Baker LH.

Eur J Cancer. 2010 Mar;46(5):863-8. doi: 10.1016/j.ejca.2010.01.016. Review.

PMID:
20138507
50.

The development and testing of a measure assessing clinician beliefs about patient self-management.

Hibbard JH, Collins PA, Mahoney E, Baker LH.

Health Expect. 2010 Mar;13(1):65-72. doi: 10.1111/j.1369-7625.2009.00571.x. Epub 2009 Nov 10.

Supplemental Content

Loading ...
Support Center